Hazard ratios and 95% confidence intervals for the incidence of total strokes (N = 6,157), non-fatal strokes (N = 6,048), and fatal strokes (N = 5,758) according to self-reported sleep duration (hours per 24 hours), men aged 25 to 74 years.

<p>Abbreviation: HR: hazard ratio, CI: confidence interval, N: Size of the underlying study population with regard to the particular stroke outcome, h: hour.</p><p>Model 1: crude model (unadjusted).</p><p>Model 2: adjusted for age (continuous) and survey (1, 2, 3, 4).</p><p>Model 3: “Socio-demographic and lifestyle model” was, in addition to model 2, further adjusted for education (low, high), physical activity (>2 h/week, 1 h/week (regular), 1 h/week (irregular), no sport), alcohol consumption (men: 0–39 g/day, ≥40 g/day; women: 0–19 g/day, ≥20 g/day), current smoking activity (yes, no).</p><p>Model 4: The full model (“health status model”) was, in addition to model 3, adjusted for BMI (continuous), hypertension (yes, no), diabetes (yes, no), dyslipidemia (yes, no).</p><p>¹ Number of incident stroke cases.</p><p>Hazard ratios and 95% confidence intervals for the incidence of total strokes (N = 6,157), non-fatal strokes (N = 6,048), and fatal strokes (N = 5,758) according to self-reported sleep duration (hours per 24 hours), men aged 25 to 74 years.</p

Prevalence (%) and mean (±standard deviation) of baseline population characteristics by sex and incident total strokes, men and women aged 25 to 74 years (N = 15,746).

<p>¹ Variable was available for 15,742 individuals.</p><p>² Variable was available for 15,732 individuals.</p><p>³ Variable was available for 10,945 individuals. Median and interquartile range.</p><p>⁴ Variable was available for 12,131 individuals.</p><p>Prevalence (%) and mean (±standard deviation) of baseline population characteristics by sex and incident total strokes, men and women aged 25 to 74 years (N = 15,746).</p

Flow chart describing the selection and subsequent loss of participants.

<p>Flow chart describing the selection and subsequent loss of participants.</p

Association of uric acid values with i-IFG, i-IGT, IFG/IGT, NDD, and known diabetes (comparisons with NGT), KORA F4 study.

<p>Odds ratio (OR) expressed per mg/dL increment in uric acid concentration; if the confidence intervals around the odds ratios overlap, then the odds ratios are not significantly different</p>†<p>Model 1: adjusted for age and sex (only total sample).</p>‡<p>Model 2: adjusted for age, sex, actual hypertension, regular smoking, physical activity, alcohol intake, and creatinine.</p>§<p>Model 3: adjusted for age, sex, actual hypertension, regular smoking, physical activity, alcohol intake, creatinine, total cholesterol, and HDL cholesterol.</p>||<p>Model 4: adjusted for age, sex, actual hypertension, regular smoking, physical activity, alcohol intake, creatinine, total cholesterol, HDL cholesterol, and BMI.</p

Mean uric acid levels stratified by reproductive parameters, the KORA F4 study (N = 1530).

<p>Abbreviations: CI: Confidence Interval, BMI: Body mass index, lsmean: least square mean.</p>*<p>the p-values (linear model) are reported for age at menarche and parity as continuous variable.</p><p>Model 1: adjusted for age (in years).</p><p>Model 2: adjusted for age (in years) and BMI (kg/m²).</p><p>Model 3: adjusted for age (in years), BMI (kg/m²), serum creatinine (mg/dl), current use of uricosuric or uricostatic medication (yes/no), alcohol consumption (>20 g/d in %), current hypertension (yes/no), HDL cholesterol (mg/dl), total cholesterol (mg/dl), history of diabetes (yes/no) and education (years).</p

Hazard ratios and 95% confidence intervals for the incidence of total strokes (N = 7,911), non-fatal strokes (N = 7,796), and fatal strokes (N = 7,456) according to self-reported symptoms of insomnia, men aged 25 to 74 years.

<p>Abbreviation: HR: hazard ratio, CI: confidence interval, N: Size of the underlying study population with regard to the particular stroke outcome.</p><p>Model 1: crude model (unadjusted).</p><p>Model 2: adjusted for age (continuous) and survey (1, 2, 3, 4).</p><p>Model 3: “Socio-demographic and lifestyle model” was, in addition to model 2, further adjusted for education (low, high), physical activity (>2 h/week, 1 h/week (regular), 1 h/week (irregular), no sport), alcohol consumption (men: 0–39 g/day, ≥40 g/day; women: 0–19 g/day, ≥20 g/day), current smoking activity (yes, no).</p><p>Model 4: The full model (“health status model”) was, in addition to model 3, adjusted for BMI (continuous), hypertension (yes, no), diabetes (yes, no), dyslipidemia (yes, no).</p><p>¹ Number of incident stroke cases.</p><p>Hazard ratios and 95% confidence intervals for the incidence of total strokes (N = 7,911), non-fatal strokes (N = 7,796), and fatal strokes (N = 7,456) according to self-reported symptoms of insomnia, men aged 25 to 74 years.</p

Reproductive parameters and uric acid levels in postmenopausal women, including women currently under hormone replacement therapy, the KORA F4 study (n = 959).

<p>Abbreviations: CI: Confidence Interval, BMI: Body mass index, lsmean: least square means.</p>*<p>the p-values (linear model) are reported for age at menarche and parity as continuous variable.</p><p>Model 1: adjusted for age (in years).</p><p>Model 2: adjusted for age (in years) and BMI (kg/m²).</p><p>Model 3: adjusted for age (in years), BMI (kg/m²), serum creatinine (mg/dl), current use of uricosuric or uricostatic medication (yes/no), alcohol consumption (>20 g/d in %), current hypertension (yes/no), HDL cholesterol (mg/dl), total cholesterol (mg/dl), history of diabetes (yes/no) and education (years).</p>a<p>n = 693, due to missing values of age at menopause.</p

Characteristics of the study population, mean (SD) and prevalences (%) of variables according to quartiles of uric acid, KORA F4 study (women 32–81 years).

<p>Abbreviations: Q: quartile, BMI: body mass index, SD: standard deviation, OC: oral contraceptives, HRT: hormone replacement therapy, HDL: high density lipoprotein.</p><p>Data are expressed as mean (SD) or percentages respectively.</p><p>p-value: chi-square test was performed to test the difference between the parameters and continuous uric acid levels.</p>a<p>defined as use of antihypertensive medication, being aware of having hypertension or blood pressure values greater than 140/90 mmHg.</p>b<p>due to the skewed distribution of creatinine, the median and interquartile range is shown.</p>c<p>defined as postmenopausal women and women under hormone replacement therapy.</p>d<p>n = 693, due to missing values of age at menopause.</p

Participants (%) with uncontrolled hypertension stratified by study and sex.

<p>Within each stratum the percentage of those with prediabetes/NDD is included (numbers in boxes). BP: blood pressure, NDD: newly diagnosed T2D.</p

Characteristics by NGT, i-IFG, i-IGT, IFG-IGT, NDD, stratified by sex.

<p>Characteristics by NGT, i-IFG, i-IGT, IFG-IGT, NDD, stratified by sex.</p